On a per-share basis, the Durham, North Carolina-based company said it had a loss of 69 cents.
The results beat Wall Street expectations. The average estimate of four analysts surveyed by Zacks Investment Research was for a loss of 82 cents per share.
The pharmaceutical company posted revenue of $2.9 million in the period, which also beat Street forecasts. Four analysts surveyed by Zacks expected $2.7 million.
Dova Pharmaceuticals shares have fallen 33 percent since the beginning of the year. In the final minutes of trading on Thursday, shares hit $19.30, a drop of 20 percent in the last 12 months.
This story was generated by Automated Insights (http://automatedinsights.com/ap) using data from Zacks Investment Research. Access a Zacks stock report on DOVA at https://www.zacks.com/ap/DOVA
Copyright 2019 The Associated Press. All rights reserved. This material may not be published, broadcast, rewritten or redistributed.